Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,059 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,059 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02293811 | Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant…(P2RX7) | N/A | terminated | Nov 18, 2014 | Centre Hospitalier Universitaire de Nice | the tissue mass of each biopsy sample was not sufficient to perform an exploratory analysis to… | Other (stated, no rule matched) |
| NCT05472506 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant… | Phase 1 | withdrawn | Jul 25, 2022 | Ikena Oncology | Sponsor Decision | Sponsor / business decision |
| NCT02923739 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With… | Phase 2 | terminated | Oct 5, 2016 | M.D. Anderson Cancer Center | The study was terminated early by the Sponsor | Other (stated, no rule matched) |
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer… | Phase 2 | terminated | Oct 30, 2020 | Jeffrey Clarke | Lack of Enrollment | Enrollment / accrual |
| NCT02762266 | Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or… | Phase 3 | terminated | May 4, 2016 | Stanford University | Business decision - funding | Funding |
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced… | N/A | withdrawn | Oct 28, 2019 | Ohio State University Comprehensive Cancer Center | PI decision | Other (stated, no rule matched) |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2… | Phase 1 | terminated | Nov 16, 2021 | HiberCell, Inc. | sponsor decision | Sponsor / business decision |
| NCT04352413 | A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based… | Phase 2 | terminated | Apr 20, 2020 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT04410874 | Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer(MUSIC-01) | Phase 1 / Phase 2 | terminated | Jun 1, 2020 | Ivan Litvinov | Inability to recruit patients/lack of funding | Enrollment / accrual |
| NCT03709082 | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2… | Phase 1 / Phase 2 | terminated | Oct 17, 2018 | University of Kansas Medical Center | Low accrual | Enrollment / accrual |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic… | Phase 2 | terminated | Mar 5, 2007 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME… | Phase 1 | terminated | Mar 18, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT06052423 | ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 25, 2023 | Hansoh BioMedical R&D Company | Research and development strategy adjustment. | Sponsor / business decision |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in… | Phase 1 / Phase 2 | terminated | Oct 29, 2021 | NKGen Biotech, Inc. | Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best… | Other (stated, no rule matched) |
| NCT05922579 | A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With… | — | terminated | Jun 28, 2023 | Ipsen | Significant and complex challenges had since been identified during recent testing phases. After… | Other (stated, no rule matched) |
| NCT05156372 | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate…(HIIT PCa) | N/A | withdrawn | Dec 14, 2021 | The University of Texas Health Science Center at San Antonio | PI left the institution, no subjects were enrolled | Investigator |
| NCT05474690 | A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of… | Phase 3 | withdrawn | Jul 26, 2022 | Henan Cancer Hospital | The new treatment plan for HER2 positive breast cancer has entered the diagnosis and treatment… | Other (stated, no rule matched) |
| NCT05292443 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated… | — | withdrawn | Mar 23, 2022 | Geneplus-Beijing Co. Ltd. | No participants were enrolled | Enrollment / accrual |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical… | Early Phase 1 | terminated | Jan 23, 2019 | Northwestern University | Lack of funding | Funding |
| NCT04624113 | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant,… | Phase 1 | terminated | Nov 10, 2020 | Washington University School of Medicine | Ipsen bought out Epizyme | Other (stated, no rule matched) |
| NCT03345784 | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper… | Phase 1 | terminated | Nov 17, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03997448 | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic… | Phase 2 | terminated | Jun 25, 2019 | Nataliya Uboha | Funder decision | Other (stated, no rule matched) |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast…(TENACITY) | Phase 2 | terminated | Jul 8, 2020 | Ayala Pharmaceuticals, Inc, | Sponsor's decision | Sponsor / business decision |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or… | Phase 1 / Phase 2 | terminated | Dec 18, 2017 | Georgetown University | Study closed due to lack of enrollment. | Enrollment / accrual |
| NCT01913275 | Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage… | N/A | withdrawn | Aug 1, 2013 | All India Institute of Medical Sciences | Lack of interest | Other (stated, no rule matched) |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT03606486 | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | N/A | terminated | Jul 30, 2018 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and… | Phase 1 / Phase 2 | terminated | Feb 6, 2018 | Cellestia Biotech AG | business reason | Sponsor / business decision |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants… | Phase 1 / Phase 2 | terminated | Jun 20, 2019 | pharmaand GmbH | Due to a change in development priorities, no further clinical development of the lucitanib plus… | Other (stated, no rule matched) |
| NCT03709771 | Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint… | — | terminated | Oct 17, 2018 | Vanderbilt University Medical Center | Study terminated due to unmet targeted accrual goals with only 2 subjects accrued out of 80 planned… | COVID-19 / pandemic |
| NCT03420521 | Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors | Phase 2 | terminated | Feb 5, 2018 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Loss of funding | Funding |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With… | Phase 1 | terminated | Aug 6, 2019 | Patrick Joseph Loehrer Sr. | Unable to proceed due to Neulasta difficulties and other complications. | Other (stated, no rule matched) |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated…(AcceleRET-MTC) | Phase 3 | withdrawn | Feb 18, 2021 | Hoffmann-La Roche | Due to several logistical challenges during start-up which could not be overcome study was… | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT04756505 | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Feb 16, 2021 | M.D. Anderson Cancer Center | Per Sponsor Request-no longer manufacturing the study drug | Drug supply |
| NCT03494803 | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of… | — | withdrawn | Apr 11, 2018 | HKGepitherapeutics | No participants enrolled, leading to insufficient patient numbers to initiate the clinical trial. | Enrollment / accrual |
| NCT03499678 | Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA | — | terminated | Apr 17, 2018 | HKGepitherapeutics | Encountered technical issues with blood plasma samples received from the hospital. | Other (stated, no rule matched) |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT04634825 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | Phase 2 | terminated | Nov 18, 2020 | MacroGenics | Based on internal review of safety data | Safety / toxicity |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Phase 1 / Phase 2 | terminated | May 6, 2022 | Fusion Pharmaceuticals Inc. | Fusion announced that it is discontinuing this study as part of a portfolio prioritization and… | Sponsor / business decision |
| NCT04341740 | Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma(WindMIL-001) | N/A | terminated | Apr 10, 2020 | University of Oklahoma | Study funding was withdrawn. | Funding |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in… | Phase 1 | terminated | May 15, 2018 | Ipsen | Due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns | Safety / toxicity |
| NCT04452396 | CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive… | N/A | terminated | Jun 30, 2020 | Barts & The London NHS Trust | Due to the Covid crisis: clinical changes in staff, bed pressures and time restraints. | COVID-19 / pandemic |
| NCT02802124 | Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma | N/A | terminated | Jun 16, 2016 | Shanghai Proton and Heavy Ion Center | For tumor locates away from GI the planned enrolled patient had been completed, but for tumor… | Enrollment / accrual |
| NCT05184283 | Utilization of MAsS in Patients Undergoing LT for HCC | — | terminated | Jan 11, 2022 | Columbia University | Discontinued by Amra Medical due to funding. | Funding |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable… | Phase 2 | terminated | Jul 12, 2013 | Albert Einstein College of Medicine | Study was terminated due to slower than anticipated accrual | Enrollment / accrual |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and… | Phase 1 | terminated | Jan 7, 2016 | SCRI Development Innovations, LLC | Clinical program was discontinued by Novartis | Other (stated, no rule matched) |
| NCT02859064 | Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors… | Phase 2 | terminated | Aug 8, 2016 | SCRI Development Innovations, LLC | Closed due to slow accrual | Enrollment / accrual |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative…(TARA) | Phase 2 | terminated | Dec 31, 2020 | Mylin A. Torres, MD | This study has been terminated due to Lack of Accrual. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 18, 2024source: clinicaltrials